Publication: A novel hybrid method named electron conformational genetic algorithm as a 4D QSAR investigation to calculate the biological activity of the tetrahydrodibenzazosines
| dc.contributor.author | Sahin, Kader | |
| dc.contributor.author | Saripinar, Emín | |
| dc.contributor.institution | Sahin, Kader, Department of Biophysics, Bahçeşehir Üniversitesi, Istanbul, Turkey | |
| dc.contributor.institution | Saripinar, Emín, Department of Chemistry, Erciyes Üniversitesi, Kayseri, Turkey | |
| dc.date.accessioned | 2025-10-05T15:48:41Z | |
| dc.date.issued | 2020 | |
| dc.description.abstract | To understand the structure–activity correlation of a group of tetrahydrodibenzazocines as inhibitors of 17β-hydroxysteroid dehydrogenase type 3, we have performed a combined genetic algorithm (GA) and four-dimensional quantitative structure–activity relationship (4D-QSAR) modeling study. The computed electronic and geometry structure descriptors were regulated as a matrix and named as electron-conformational matrix of contiguity (ECMC). A chemical property-based pharmacophore model was developed for series of tetrahydrodibenzazocines by EMRE software package. GA was employed to choose an optimal combination of parameters. A model has been developed for estimating anticancer activity quantitatively. All QSAR models were established with 40 compounds (training set), then they were considered for selective capability with additional nine compounds (test set). A statistically valid 4D-QSAR ((Formula presented.), (Formula presented.) and q2 = 0.650) with good external set prediction was obtained. © 2020 Elsevier B.V., All rights reserved. | |
| dc.identifier.doi | 10.1002/jcc.26154 | |
| dc.identifier.endpage | 1104 | |
| dc.identifier.issn | 1096987X | |
| dc.identifier.issn | 01928651 | |
| dc.identifier.issue | 11 | |
| dc.identifier.pubmed | 32058616 | |
| dc.identifier.scopus | 2-s2.0-85079436464 | |
| dc.identifier.startpage | 1091 | |
| dc.identifier.uri | https://doi.org/10.1002/jcc.26154 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.14719/10490 | |
| dc.identifier.volume | 41 | |
| dc.language.iso | en | |
| dc.publisher | John Wiley and Sons Inc. P.O.Box 18667 Newark NJ 07191-8667 | |
| dc.relation.source | Journal of Computational Chemistry | |
| dc.subject.authorkeywords | Drug Design | |
| dc.subject.authorkeywords | Genetic Algorithm | |
| dc.subject.authorkeywords | Molecular Modeling | |
| dc.subject.authorkeywords | Pharmacophore | |
| dc.subject.authorkeywords | Tetrahydrodibenzazocines | |
| dc.subject.authorkeywords | Hydroxysteroid Dehydrogenase | |
| dc.subject.authorkeywords | 17-hydroxysteroid Dehydrogenases | |
| dc.subject.authorkeywords | Antineoplastic Agents | |
| dc.subject.authorkeywords | Azocines | |
| dc.subject.authorkeywords | Enzyme Inhibitors | |
| dc.subject.authorkeywords | Bioactivity | |
| dc.subject.authorkeywords | Bioinformatics | |
| dc.subject.authorkeywords | Computational Chemistry | |
| dc.subject.authorkeywords | Conformations | |
| dc.subject.authorkeywords | Dehydrogenation | |
| dc.subject.authorkeywords | Molecular Graphics | |
| dc.subject.authorkeywords | Molecular Modeling | |
| dc.subject.authorkeywords | Pharmacodynamics | |
| dc.subject.authorkeywords | Anticancer Activities | |
| dc.subject.authorkeywords | Drug Design | |
| dc.subject.authorkeywords | Hydroxysteroid Dehydrogenase | |
| dc.subject.authorkeywords | Optimal Combination | |
| dc.subject.authorkeywords | Pharmacophore Modeling | |
| dc.subject.authorkeywords | Pharmacophores | |
| dc.subject.authorkeywords | Quantitative Structures | |
| dc.subject.authorkeywords | Tetrahydrodibenzazocines | |
| dc.subject.authorkeywords | Genetic Algorithms | |
| dc.subject.authorkeywords | Antineoplastic Agent | |
| dc.subject.authorkeywords | Azocine Derivative | |
| dc.subject.authorkeywords | Enzyme Inhibitor | |
| dc.subject.authorkeywords | Hydroxysteroid Dehydrogenase | |
| dc.subject.authorkeywords | Algorithm | |
| dc.subject.authorkeywords | Chemistry | |
| dc.subject.authorkeywords | Conformation | |
| dc.subject.authorkeywords | Drug Screening | |
| dc.subject.authorkeywords | Electron | |
| dc.subject.authorkeywords | Molecular Model | |
| dc.subject.authorkeywords | Quantitative Structure Activity Relation | |
| dc.subject.authorkeywords | 17-hydroxysteroid Dehydrogenases | |
| dc.subject.authorkeywords | Algorithms | |
| dc.subject.authorkeywords | Antineoplastic Agents | |
| dc.subject.authorkeywords | Azocines | |
| dc.subject.authorkeywords | Drug Screening Assays, Antitumor | |
| dc.subject.authorkeywords | Electrons | |
| dc.subject.authorkeywords | Enzyme Inhibitors | |
| dc.subject.authorkeywords | Models, Molecular | |
| dc.subject.authorkeywords | Molecular Conformation | |
| dc.subject.authorkeywords | Quantitative Structure-activity Relationship | |
| dc.subject.indexkeywords | Bioactivity | |
| dc.subject.indexkeywords | Bioinformatics | |
| dc.subject.indexkeywords | Computational chemistry | |
| dc.subject.indexkeywords | Conformations | |
| dc.subject.indexkeywords | Dehydrogenation | |
| dc.subject.indexkeywords | Molecular graphics | |
| dc.subject.indexkeywords | Molecular modeling | |
| dc.subject.indexkeywords | Pharmacodynamics | |
| dc.subject.indexkeywords | Anticancer activities | |
| dc.subject.indexkeywords | Drug Design | |
| dc.subject.indexkeywords | Hydroxysteroid dehydrogenase | |
| dc.subject.indexkeywords | Optimal combination | |
| dc.subject.indexkeywords | Pharmacophore modeling | |
| dc.subject.indexkeywords | Pharmacophores | |
| dc.subject.indexkeywords | Quantitative structures | |
| dc.subject.indexkeywords | tetrahydrodibenzazocines | |
| dc.subject.indexkeywords | Genetic algorithms | |
| dc.subject.indexkeywords | antineoplastic agent | |
| dc.subject.indexkeywords | azocine derivative | |
| dc.subject.indexkeywords | enzyme inhibitor | |
| dc.subject.indexkeywords | hydroxysteroid dehydrogenase | |
| dc.subject.indexkeywords | algorithm | |
| dc.subject.indexkeywords | chemistry | |
| dc.subject.indexkeywords | conformation | |
| dc.subject.indexkeywords | drug screening | |
| dc.subject.indexkeywords | electron | |
| dc.subject.indexkeywords | molecular model | |
| dc.subject.indexkeywords | quantitative structure activity relation | |
| dc.subject.indexkeywords | 17-Hydroxysteroid Dehydrogenases | |
| dc.subject.indexkeywords | Algorithms | |
| dc.subject.indexkeywords | Antineoplastic Agents | |
| dc.subject.indexkeywords | Azocines | |
| dc.subject.indexkeywords | Drug Screening Assays, Antitumor | |
| dc.subject.indexkeywords | Electrons | |
| dc.subject.indexkeywords | Enzyme Inhibitors | |
| dc.subject.indexkeywords | Models, Molecular | |
| dc.subject.indexkeywords | Molecular Conformation | |
| dc.subject.indexkeywords | Quantitative Structure-Activity Relationship | |
| dc.title | A novel hybrid method named electron conformational genetic algorithm as a 4D QSAR investigation to calculate the biological activity of the tetrahydrodibenzazosines | |
| dc.type | Article | |
| dcterms.references | Poirier, Donald, Inhibitors of 17β-Hydroxysteroid dehydrogenases, Current Medicinal Chemistry, 10, 6, pp. 453-477, (2003), Scher, Howard I., Targeting the androgen receptor: Improving outcomes for castration-resistant prostate cancer, Endocrine-Related Cancer, 11, 3, pp. 459-476, (2004), Sha, Jiaho A., Sequence of mouse 17β-hydroxysteroid dehydrogenase type 3 cDNA and tissue distribution of the type 1 and type 3 isoform mRNAs, Journal of Steroid Biochemistry and Molecular Biology, 60, 1-2, pp. 19-24, (1997), Koh, Eitetsue, Differential expression of 17β-hydroxysteroid dehydrogenase isozyme genes in prostate cancer and noncancer tissues, Prostate, 53, 2, pp. 154-159, (2002), Spires, Thomas E., Identification of novel functional inhibitors of 17β-hydroxysteroid dehydrogenase type III (17β-HSD3), Prostate, 65, 2, pp. 159-170, (2005), Geissler, Wayne M., Male pseudohermaphroditism caused by mutations of testicular 17β–hydroxysteroid dehydrogenase 3, Nature Genetics, 7, 1, pp. 34-39, (1994), Luu-Thé, Van, Characteristics of human types 1, 2 and 3 17β-hydroxysteroid dehydrogenase activities: Oxidation/reduction and inhibition, Journal of Steroid Biochemistry and Molecular Biology, 55, 5-6, pp. 581-587, (1995), Robert, Jacques, Multidrug Resistance Reversal Agents, Journal of Medicinal Chemistry, 46, 23, pp. 4805-4817, (2003), Hassan, Saadia Bashir, Cytotoxic activity of a new paclitaxel formulation, Pacliex, in vitro and in vivo, Cancer Chemotherapy and Pharmacology, 55, 1, pp. 47-54, (2005), Jin, Shan, Computer-based de novo design, synthesis, and evaluation of boronic acid-based artificial receptors for selective recognition of dopamine, ChemBioChem, 9, 9, pp. 1431-1438, (2008) | |
| dspace.entity.type | Publication | |
| local.indexed.at | Scopus | |
| person.identifier.scopus-author-id | 57211550406 | |
| person.identifier.scopus-author-id | 6603068833 |
